Yoon SM, Luterstein E, Chu FI, et al. - Since stereotactic body radiotherapy (SBRT) delivers ablative doses with excellent local control, however, implementing SBRT for abdominal and pelvic tumors has been limited by the risk for treatment-related gastrointestinal toxicity, researchers conducted this retrospective study to report the clinical outcomes of stereotactic MRI-guided adaptive radiotherapy (SMART) for primary and metastatic tumors in the abdomen and pelvis. From November 2014 to August 2017, a single institution treated the first 106 consecutive patients with 121 tumors in the abdomen and pelvis with SMART. The most common acute toxicities were fatigue, nausea, and pain. The 2-year LC rate was 74% on a per-lesion basis after a median follow-up of 20.4 months. For tumors in the abdomen and pelvis treated with SMART, favorable LC and PFS outcomes were observed with minimal morbidity.